AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03517137 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
Study NCT02546908 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
Study NCT00656500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard brief advice
Description: Brief general assistance with smoking cessation
Study NCT00656500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline intervention
Description: Brief intervention designed specifically to encourage quitline utilization
Study NCT00996190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
Study NCT01236833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: 2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
Study NCT02625831 — intervention group
Intervention type: OTHER
Intervention: Biological analysis
Description: Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies
Study NCT02739542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecfidera
Description: Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
Study NCT02739542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
Study NCT00344032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT02994056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT02994056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
Study NCT03218592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc Pill
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Study NCT03218592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pill
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Study NCT03218592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Pill
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Study NCT03340168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bisphenol-S
Description: Oral and dermal exposure in volunteers
Study NCT00697775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine Formulation A
Description: Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
Study NCT00697775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine Formulation B
Description: 2-dose intramuscular injection
Study NCT00697775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
Study NCT00697775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
Study NCT02366221 — intervention group
Intervention type: OTHER
Intervention: 60-minute visit to the outpatient clinic
Description: An interview, an injury-specific physical exam and/or a set of xrays.
Study NCT02366221 — intervention group
Intervention type: OTHER
Intervention: Phone Interview
Description: If subject cannot return to office in Boston, researcher may conduct interview over the phone.
Study NCT01621490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01621490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT04561128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819
Description: SHR-1819 will be subcutaneously administered with different dose levels
Study NCT04561128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered with different dose levels
Study NCT04159324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
Description: the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
Study NCT02053259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goals
Study NCT02053259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement
Study NCT02053259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Goals
Study NCT02053259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Goals
Study NCT02115061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Treatment: coil + cyanoacrylate
Description: This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
Study NCT02115061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment: cyanoacrylate
Description: This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
Study NCT00365547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
Study NCT00365547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Topotecan 4 mg/m\^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
Study NCT01741571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS guided FNA with and without suction
Description: Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied.
Study NCT01741571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS guided FNA with and without suction
Description: Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied.
Study NCT01669200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglyceride Oil
Description: Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
Study NCT01669200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
Study NCT02370069 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
Study NCT02651649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
Study NCT01630356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-person counseling
Description: The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
Study NCT01630356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demonstration of PM2.5 Pollution
Description: The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
Study NCT01630356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Counseling Calls
Description: Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
Study NCT01630356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed material
Description: The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency.
Study NCT01630356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed material
Description: The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency.
Study NCT02929615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Study NCT00911586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Study NCT03693209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Description: VHS with a general anger trigger and 10 anger management strategies
Study NCT03693209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Description: VHS with 10 specific anger triggers and 10 anger management strategies
Study NCT03219671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg every 2 weeks
Study NCT03219671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg every 6 weeks
Study NCT00168493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressants primarily selective serotonin reuptake inhibitors
Description: normal clinical dosages used according to clinical response as determined by a psychiatrist
Study NCT00723125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
Study NCT00723125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
Study NCT00723125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
Study NCT01036243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test formula 1
Description: hydrolyzed formula with probiotics
Study NCT01036243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: test formula 2
Description: acidified hydrolyzed formula
Study NCT01036243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: test formula 3
Description: hydrolyzed formula without probiotics
Study NCT01036243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: reference formula
Description: standard infant formula
Study NCT05290012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
Study NCT01095133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
Study NCT01095133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiloride
Description: dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
Study NCT01095133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
Study NCT01621828 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: video
Description: a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
Study NCT01621828 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: leaflet
Description: a written leaflet, about the operating room experience and environment.
Study NCT04436653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Replacement System
Description: To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
Study NCT01240395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Description: MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
Study NCT04555499 — intervention group
Intervention type: OTHER
Intervention: Standardized neurological examination
Study NCT04049006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex treatment
Description: The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
Study NCT03552042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterclockwise program
Description: A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
Study NCT03552042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
Study NCT01489059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study NCT03994484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle